Ganesh Consumer Products Ltd Forensic Report - SOIC x StockScans Report

as of Aug 2026

Ganesh Consumer Products' audited record shows real cash generation, with cumulative operating cash flow exceeding cumulative profit across FY22-FY26. But the IPO's core purpose has stalled: of ₹45 crore earmarked for a new manufacturing unit, only ₹2.46 crore was deployed nine months after receipt, while the company paid out 48% of profit as dividends. A CARE Ratings monitoring report also flags ₹7.70 crore of IPO proceeds used without requisite approvals.

Key findings

  1. IPO capex stalled, 48% of profit paid out as dividends Major - Of ₹45 crore earmarked for a roasted gram flour and gram unit in Darjeeling, only ₹2.46 crore was deployed as at March 31, 2026, leaving ₹42.54 crore unutilised in fixed deposits and bank balances. The Board approved a revised timeline on May 22, 2026 for deployment through Fiscal 2027. The company declared an interim dividend of ₹2.50 per share on November 6, 2025 and recommended a final dividend of ₹2.50 per share on May 22, 2026, a total payout of 48% for FY2025-26.
  2. Reported debt is minimal, but economic obligations are larger Major - CARE Ratings assigned 'CARE A+; Stable / CARE A1+' to ₹208.00 crore of bank facilities on 4 May 2026. Non-fund based working capital utilisation was high at \~85% for the 12 months ended February 2026. Deposits pledged against bank guarantees stood at ₹43.70 lakh as of 31st March 2026, up from ₹38.32 lakh a year earlier.
  3. NCLT scheme consolidated promoter control without quantified impact Major - An NCLT Kolkata Scheme of Arrangement, ordered 5th April 2024, transferred GCPL shares held by promoter-linked transferor companies to Srivaru Agro Private Limited on 5th August 2024. Loans and advances given by GCPL to two transferor companies were also transferred to Srivaru Agro on 21st June 2024. No quantified impact of the control transfer was disclosed.
  4. CARE Ratings flags ₹7.70 crore of IPO proceeds used without approvals Major - CARE Ratings' monitoring report for the quarter ended 31 March 2026 noted the company utilised ₹1.86 crore towards marketing expenses and ₹5.84 crore towards funding growth opportunities without requisite approvals. The company itself stated no penalties or strictures were imposed by Stock Exchanges, SEBI or any statutory authority during FYs 2024-2026.
  5. Promoter family consolidates board control and pay; dissent negligible Minor - Promoter shareholding stood at 64.08% as on March 31, 2026, with none under pledge. Devansh Mimani, son of Chairperson & MD Manish Mimani, was appointed Non-Executive Non-Independent Director effective March 16, 2026, with shareholder-approved remuneration of ₹6 lakhs per annum. Public non-institutional votes against his appointment were just 0.1446% of their votes polled.
  6. Clean audit opinions with two audit-trail exceptions and one filing variance Minor - SINGHI & Co. issued an unqualified opinion on the FY ended March 31, 2026 financial statements, dated May 22, 2026. The audit-trail exception notes the edit log was not enabled at database level for the payroll software, with no instances of tampering otherwise. CARO reports working capital quarterly returns filed with lenders were not in agreement with books of account because statements were filed on a provisional basis.

What to watch

Bottom line: This is a cash-generative business with a clean audit opinion and a promoter group that has increased its stake. The risk is not in the profit line but in capital allocation: the IPO's stated purpose remains largely unspent, a monitoring agency has flagged unauthorised use of proceeds, and the company is simultaneously returning cash to shareholders. Watch the next CARE report and whether the ₹42.54 crore gets deployed as promised.